Edwards Lifesciences Corporatio
Performance
株価チャート
業績・財務
業績・財務
| 売上高 | $1.65B |
| 営業利益 | $514.70M |
| 税引前利益 | $459.00M |
| 純利益 | $380.70M |
| 営業利益率 | 31.2% |
| ROE | 3.7% |
| ROA | 2.9% |
| 自己資本比率 | 77.5% |
| 総資産 | $13.32B |
| 純資産 | $10.33B |
業績推移
売上・利益の推移
ROE・ROA の推移
詳細指標
詳細指標
| ROIC | — |
| ROE | 10.46% |
| ROA | 8.27% |
| FCFマージン | 14.31% |
| 粗利益率 | 77.87% |
| 営業利益率 | 31.22% |
| 営業CFマージン | 21.55% |
| 配当性向 | 0.00% |
| 配当成長率(3年) | — |
| Net Debt/EBITDA | 6.81 |
| 実効税率 | — |
| 自社株買い傾向 | — |
バランスシート
バランスシート
| ネットキャッシュ | -$262.60M |
| NC比率 | -0.5% |
| 流動資産 | $6.23B |
| 有価証券 | $285.60M |
| 現金 | $2.45B |
| 負債総額 | $2.99B |
| 時価総額(BS時点) | $52.09B |
企業情報
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
| ウェブサイト | https://www.edwards.com |
| CEO | Mr. Bernard J. Zovighian |
| 従業員数 | 16,000人 |
| 住所 | One Edwards Way, Irvine, 92614, United States |
| 電話番号 | 949 250 2500 |
| 取引所 | NYQ |
| 国 | United States |